As the U.S. Court of Appeals for the Federal Circuit heard oral arguments on whether isolated genes should be patentable, The National Law Journal asked those involved in the case–either directly or as an amicus– to provide their opinions on the matter. David S. Forman, Ph.D., senior counsel at Finnegan, examined the government’s position and how their proposed limits on gene patenting could negatively affect scientific research and progress in the biotechnology and chemical industries. “Problematically, the government argues that any molecule with a structure that can be found somewhere within a natural molecule is also unpatentable, even though it is only made by man and never occurs in nature.”
Commentary
Patenting Lessons Learned from Representing 200 of Israel’s Leading Companies
September 19, 2022
James R. Barney
May 9, 2016
Justin A. Hendrix
The UK Legal 500 London Ranks Finnegan for Intellectual Property
September 18, 2015
Charles T. Collins-Chase
September 17, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.